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Serum proteome predicts viral response in HCV-1 653Results: Seventy-four patients (54%) had a sustained virological response (SVR), whereas 62 did
not. We identified three protein peaks in pretreatment sera where the expression levels signif-
icantly differed between SVR and non-SVR (p < 0.05). Using the class prediction tool composed
of the three protein peaks, we were able to correctly predict SVR in 95% of validation group
patients with sensitivity Z 95%, specificity Z 56.3%, positive predictive value Z 73.1%, and
negative predictive value Z 90%. We also identified a set of 20 protein peaks where the
expression levels significantly differed in pretreatment sera between patients with nonre-
sponse (NR) and virological response (SVR plus relapse; p < 0.05). Using the class prediction
tool composed of these 20 protein peaks, we were able to correctly predict virological NR in
82% of validation group patients with sensitivityZ 100%, specificityZ 82%, positive predictive
value Z 92.6%, and negative predictive value Z 100%.
Conclusion: Pretreatment serum proteome allows prediction of SVR and NR to PegIFN plus RBV
treatment in HCV-1b patients.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Hepatitis C virus (HCV) infection is the leading cause of viral
hepatitis worldwide. Although infection is often asymptom-
atic, the majority of infected patients progress to chronic
hepatitis, which may lead to liver cirrhosis and eventually to
the development of hepatocellular carcinoma (HCC).1e3
The current standard of care is pegylated interferon
(PegIFN) in combination with ribavirin (RBV), which has
yielded a sustained virological response (SVR) rate of
50e79% in patients with genotype 1 infection.4e7 Genotype
1 is the prevalent genotype in Japan, Taiwan, and Southern
and Eastern Europe.8,9 The SVR rate is 80e95% in those
infected with HCV genotypes 2 and 3.4e6,10 Interferon-
based antiviral therapy reduces HCC development and
liver-related morbidity/mortality in chronic HCV infection,
particularly in those patients with SVR.11,12
Although remarkable progress has been made in its
effectiveness, the therapy is expensive and is often associ-
ated with side effects that may lead to discontinuation of
treatment.4e6 Therefore, it would be useful if one could
predict which patients will respond to antiviral therapy. To
date, it has been shown that sex, age, viral load, on-
treatment virological response, liver cirrhosis, IFN recep-
tor, liver interleukin-8 (IL-8) mRNA expression, and HCV ge-
notype are associated with SVR when using interferon-based
treatment.4e7,13,14 Recent genome-wide association studies
(GWAS) showed that polymorphisms in or near the IL-28B
gene strongly determine the response to HCV therapy in
HCV-1 patients.15e17 Subsequent studies also confirmed that
IL-28B polymorphisms are correlated with the response to
interferon-based therapy in HCV-1 patients in Taiwan.18e20
Matrix-assisted laser desorption/ionization time-of-flight
mass spectrometry (MALDIeTOF/MS) provides a potentially
powerful tool for global visualization of the proteome in a
biological milieu.21,22 Comparison of protein profiles accord-
ing to patient phenotypes led to the identification of isolated
or clustered protein peaks that characterized pathological
conditions. Paradis et al23 reported that proteome kinetics
was significantly different in the serum of patients according
to treatment response and that pretreatment serum prote-
ome profiles could be used to predict SVR. By using liquid
chromatography mass spectrometry (LCeMS), Patel et al24
identified pretreatment metaproteins that could predictSVR to PegIFN and RBV combination therapy. However, the
available information on the association between serum
proteome profiles and the SVR to PegIFN plus RBV therapy in
chronic hepatitis C patients remains limited.23,24 In this study
we investigated theassociationbetween changes in the serum
proteome and virological response in chronic HCV-1b patients
treated with PegIFN plus RBV.
This study was approved by the Chang Gung Memorial
Hospitalethics committee in accordance with the Declara-
tion of Helsinki.
Materials and methods
First, we screened patients who fulfilled the following
criteria: (1) the diagnosis of chronic hepatitis C based on
anti-HCV antibody positive status [by third-generation
enzyme-linked immunosorbent assay (ELISA);Abbott Labo-
ratories, Chicago, IL, USA]; (2) had a baseline histological
examination; and (3) had detectable serum HCV RNA. Pa-
tients with a positive test for serum hepatitis B surface an-
tigen, a positive HIV test, other causes of hepatocellular
injury (such as alcoholism, autoimmune hepatitis, primary
biliary cirrhosis, a history of treatment with hepatotoxic
drugs, or a need for hemodialysis) were excluded. After
initial screening, there were 1032 patients with chronic HCV
infectionwho received PegIFN plus RBV combination therapy
between April 2002 and July 2008. During this time period,
the Bureau of National Health Insurance of Taiwan provided
reimbursement for 24 weeks for PegIFN plus RBV therapy to
all chronic hepatitis C patients, irrespective of their geno-
types and on-treatment virological response. Therefore,
most patients received a fixed duration of a 24-week treat-
ment, except patients who could afford self-paid treatment
if they were genotype 1 and did not have rapid virological
response (defined as serum HCV RNA undetectable at Week
4). Of these patients, 545 had genotype 1b infection. Of the
545 patients, 401 had received a fixed duration therapy of
PegIFN plus RBV for 24 weeks. Of the 401 patients, 267 pa-
tients had good adherence (received more than 80% of the
standard dose and duration of PegIFN and RBV). Of these
patients, 136 who were followed up for 24 weeks post-
treatment and had pretreatment serum available were
enrolled and these patients were randomly divided into
training and validation groups of 68 patients each.
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Kenilworth, NJ, USA) 1.5 mg/kg or PegIFN a-2a (Pegacys;
Roche, Basel, Switzerland) 180 mg was given subcutaneously
once weekly. Ribavirin (Rebetol, Schering-Plough, Auxerre,
France; or Copegus, Roche) 1000 mg was administered
orally per day in patients who weighed less than 75 kilo-
grams and 1200 mg orally per day in those who weighed
more than 75 kilograms.
HCV RNA was determined by PCR-based assay (Cobas
Amplicor Hepatitis C Virus Test, version 2.0; Roche Molec-
ular Systems, Branchburg, NJ, USA). SVR was defined as
undetectable serum HCV RNA 24 weeks after treatment.
Nonresponse (NR) was defined as detectable serum HCV
RNA at the end of treatment. Serum samples were ali-
quoted and stored at 80 C until MALDI analysis.
HCV genotyping
Genotyping of HCV was performed by line-probe assay (Inno
LiPA HCV II; Innogenetics, Ghent, Belgium), which was
based on reverse hybridization of PCR amplicons on a
nitrocellulose strip coated with genotype-specific oligonu-
cleotide probes.25
Liver histology
Liver biopsies were performed within 6 months treatment.
Hepatic inflammation and fibrosis were assessed using the
Knodell histological activity index (HAI).26
Serum pretreatment with magnetic beads
For each patient, serum was sampled prior to starting
treatment and at the end of treatment. For each sample,
5 mL of serum was prefractionated using magnetic-bead
based weak cation exchange chromatography (MB-WCX;
Bruker Daltonics), providing the best serum peptide profiles
in this study based on the ion intensity, peptide numbers,
and resolutions of the peptide peaks. The magnetic beads
were supplied in a standard kit with standard protocol and
washing buffers. A 5-mL serum sample was mixed with 10 mL
of binding buffer. Then, 10 mL of MB-WCX beads were added
to this solution and it was carefully mixed by pipetting it
into a standard thin-walled PCR tube. Next, the tube was
placed in a magnetic separator to allow separation of the
beads and unbound solution, and then the supernatant was
removed. The beads were then washed using 100 mL wash
buffer, and the proteins and peptides were eluted from the
magnetic beads using 5 mL of elution buffer. Next, 5 mL of
stabilization buffer was added to the eluate. The eluted
sample was diluted 1:10 in matrix solution containing 0.3 g/
L a-cyano-4-hydroxycinnamic acid in ethanol:acetone 2:1.
After dilution, 0.5 mL of the mixture was spotted onto a
600 mm diameter AnchorChip target plate (Bruker Dal-
tonics) and allowed to air dry at room temperature.
MALDIeTOF peptide profiles
After processing the serum samples as outlined above, the
serum peptide profiles were analyzed using an Ultraflex
MALDIeTOF mass spectrometer (Bruker, Bremen, Germany)equipped with a 337-nm nitrogen laser. Strict quality con-
trol runs were executed using calibrants of the standard
peptide and protein mixture to assess and ensure the ac-
curacy and reproducibility of the serum peptide profiles.
Ionization was performed by irradiation with a nitrogen
laser operated at 50 Hz. Spectrum detection was done in
the linear mode and external calibration was performed
using a defined set of peptide/protein calibration standards
(Bruker Daltonics) in the range of 1000e12,000 daltons
(Da). Spectra were obtained with 500 shots from fixed laser
power under optimized instrument settings to generate
quality raw data. Data was obtained using FlexControl
software (Bruker Daltonics, Billerica, Massachusetts, USA).Class prediction and statistical analysis
We analyzed each spectrum obtained from MALDIeTOF/MS
with flexAnalysis and ClinPro Tools version 2.0 bioinfor-
matics software (Bruker Daltonics). The analysis started
with a raw data pretreatment, which included normaliza-
tion of a set of spectra, recalibration of spectra by a total
average spectrum calculation, peak area detection on the
total average spectrum, and normalization of peak areas. In
brief, all spectra were processed by automatic baseline
subtraction, peak detection, recalibration, and peak area
calculation based on predefined settings. The criteria for
peak detection were as follows: a signal-to-noise ratio >5,
a 2-Da peak width filter, and a maximum peak number of
200. A class prediction model was set up using a genetic
algorithm combined with a k-nearest neighbor method to
analyze the mass spectra obtained from the HCV-1b pa-
tients. Using this method, we selected the optimized peaks
to establish the classification model. To determine the ac-
curacy of the class prediction, a cross-validation was per-
formed by introducing additional independent cohorts
(validation group). With function presets in the software,
the pretreated data were visually and statistically analyzed
using ClinPro Tools version 2.0 bioinformatics software
(Bruker Daltonics). The data in the peak areas were
analyzed statistically for two-class comparisons or for
multiple-class comparisons with the Wilcoxon test and the
Kruskal-Wallis test, respectively. Calculated p < 0.05 were
considered to be statistically significant.
We compared the differences in baseline characteristics
between patients with SVR and non-SVR by Chi-square test
and Student t test. Independent factors that may have
influenced the SVR were identified using stepwise multiple
logistic regression analysis. A p value < 0.05 was considered
statistically significant.Results
Patient baseline characteristics
Of the 136 HCV-1b patients, 86 were male and 50 were
female. There was a mean age of 56.5  9.8 years. Seventy-
four patients (54%) had SVR whereas 62 did not. A com-
parison of the baseline characteristics of the training and
validation groups is shown in Table 1.26
Table 1 Comparisons of the baseline characteristics of the training and validation groups in genotype 1b patients.
Variables Training group (n Z 68) Validation group (n Z 68) p value
SVR/non-SVR 37/31 37/31 > 0.99
Male: female 42:26 44:24 0.722
Age (y) 56.0  12.3 56.6  10.4 0.793
Necroinflammation scores 7.7  4.6 7.5  2.0 0.560
Fibrosis scores 2.3  1.2 2.2  1.4 0.812
ALT (IU/L) 156  74 158  91 0.879
Hepatic inflammation and fibrosis were assessed by the Knodell histological activity index (HAI).26
ALT Z alanine aminotransferase; SVR Z sustained virological response.
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patients with SVR and non-SVR
Of the 68 patients in the training group, 37 patients had
SVR. A comparison of the baseline characteristics of SVR
and non-SVR patients is shown in Table 2.26 The mean
fibrosis score in SVR patients in the training group was
1.84  1.068, which was significantly lower than non-SVR
patients in the training group (2.81  1.167), p Z 0.001.
Stepwise multiple logistic regression analysis of the factors
[age, sex, alanine aminotransferase (ALT) levels, liver
fibrosis, and inflammation stage] revealed that fibrosis
[odds ratio (OR), 0.42; 95% confidence interval (CI),
0.25e0.72; pZ 0.0017] was the only independent predictor
of SVR (Table 3).26Univariate and multivariate analyses for SVR in the
validation group
There were no significant differences in baseline features
between SVR and non-SVR patients (Table 4).26 The mean
fibrosis score in SVR patients in the validation group was
2.11  1.197, which was not significantly different from
non-SVR patients in the validation group (2.39  1.498),
p Z 0.396.Table 2 Comparisons of baseline features in training
group patients with SVR and non-SVR.
SVR (n Z 37) Non-SVR
(n Z 31)
p value
Sex (male: female) 24:13 18:13 0.5655
Age (y) 53.7  14.2 58.9  8.9 0.0742
ALT (IU/L) 157  70 154  79 0.8983
Necroinflammation
scores
7.6  1.6 7.7  1.6 0.6579
Fibrosis scores
1 21 (56.76%) 6 (19.35%) 0.003
2 4 (10.81%) 6 (19.35%)
3 9 (24.32%) 7 (22.58%)
4 3 (8.11%) 12 (38.71%)
Hepatic inflammation and fibrosis were assessed by the Knodell
histological activity index (HAI).26
ALT Z alanine aminotransferase; SVR Z sustained virological
response.Significant differences between the pretreatment
serum protein profile of SVR and non-SVR patients
We analyzed whether the pretreatment serum protein
profile could help to predict antiviral treatment response.
Pretreatment sera protein profiles of SVR (nZ 37) and non-
SVR (nZ 31) patients in the training group were compared.
We identified a set of three protein peaks in pretreatment
sera, with levels of expression that significantly differed
between the SVR and non-SVR patients (p < 0.05). These
protein peaks were m/z 6003, 4602, and 10,070 Da (Table
5). Using the class prediction tool (ClinPro Tools version
2.0 bioinformatics software; Bruker Daltonics) composed of
these three protein peaks, we were able to correctly pre-
dict SVR in 95% of validation group patients with
sensitivity Z 95%, specificity Z 56.3%, positive predictive
value Z 73.1%, and negative predictive value Z 90%.
Differences between the pretreatment serum
protein profile of nonresponders and virological
responders
Pretreatment serum protein profiles of nonresponder
(n Z 8) and virological responder (n Z 60) patients in the
training group were compared. A set of 20 protein peaks in
pretreatment sera was identified, with the levels of
expression significantly differing between nonresponders
and virological responders (p < 0.05). These protein peaks
were m/z 6003, 5432, 10,069, 4569, 5447, 6024, 3472, 4413,
5248, 7805, 4151, 6669, 2524, 1627, 3241, 5337, 3820, 5943,
4732, and 2783 Da (Table 6). Using the class prediction toolTable 3 Multivariate analysis for SVR in training group.
Factors Multivariate
Odds ratio (95%CI) p value
Sex (Male/Female) 1.06 (0.33e3.42) 0.9262
Age 0.97 (0.92e1.02) 0.1715
ALT 1.00 (1.00e1.01) 0.2758
Fibrosis 0.42 (0.25e0.72) 0.0017
Necroinflammation 1.20 (0.82e1.78) 0.3506
Hepatic inflammation and fibrosis were assessed by the Knodell
histological activity index (HAI).26
ALT Z alanine aminotransferase; SVR Z sustained virological
response.
Table 4 Univariate and multivariate analyses for SVR in validation group.
Factors Univariate Multivariate
Odds ratio (95%CI) p value Adjusted odds ratio (95%CI) p value
Sex (male/female) 1.32 (0.49, 3.57) 0.5899 1.48 (0.52, 4.21) 0.4636
Age 1.01 (0.97, 1.06) 0.6690 1.02 (0.97, 1.07) 0.5154
ALT 1.01 (1.00, 1.01) 0.1235 1.01 (1.00, 1.01) 0.1225
Fibrosis 0.85 (0.59, 1.23) 0.2902 0.76 (0.50, 1.16) 0.1989
Necroinflammation 1.07 (0.83, 1.36) 0.6145 1.08 (0.80, 1.44) 0.6303
Hepatic inflammation and fibrosis were assessed by the Knodell histological activity index (HAI).26
ALT Z alanine aminotransferase; SVR Z sustained virological response.
Table 6 Peptide peaks which were significantly different
between the serum protein profile of virological responders




Virological responders Non-responders p valuea
Patients Patients
6003 3.83 42.74 0.00362
5432 2.6 26.65 0.00362
10,069 2 9.81 0.00362
4569 7.06 30.7 0.00435
5447 3.49 47.72 0.00543
6024 2.79 19.76 0.0125
3472 8.39 22.45 0.0156
4413 7.06 45.83 0.0205
5248 22.45 11.22 0.0205
656 Y.-H. Yen et al.(ClinPro Tools version 2.0 bioinformatics software; Bruker
Daltonics) composed of these 20 protein peaks, we were
able to correctly predict virological NR in 82% of validation
group patients with sensitivity Z 100%, specificity Z 82%,
positive predictive value Z 92.6%, and negative predictive
value Z 100%.
The effect of virological response on longitudinal
serum proteomic profiles
We compared longitudinal serum protein profiles under
antiviral therapy based on virological responses in training
group patients. When comparing serum proteome profiles
prior to treatment versus at the end of treatment in viro-
logical responders, it was found that among the 226 protein
peaks, 7 (m/z 9288, 4614, 8141, 9326, 7765, 7805, 4644 Da)
varied in intensity with all the peaks decreasing signifi-
cantly under treatment (p < 0.05) (Fig. 1; Table 7).When
comparing serum proteome profiles prior to treatment
versus at the end of treatment in virological nonresponders,
it was found that among 84 protein peaks, no peaks varied
significantly in intensity.
Discussion
Identifying factors predictive of virological response to
antiviral therapy may allow for individualized modifications
of treatment regimens, which subsequently could improve
treatment response. In our study, based on genetic algo-
rithm analysis, classification models using a group of three
peptides were developed to predict SVR in 95% of patientsTable 5 Peptide peaks which were significantly different
between the pretreatment serum protein profiles of SVR
and non-SVR patients.
m/z mass, daltons Mean area
SVR Non-SVR p valuea
Patients Patients
6003 3.41 21.45 0.0111
4602 10.48 20.09 0.0141
10,070 1.98 7.34 0.026
SVR Z sustained virological response.
a Wilcoxon or Kruskal-Wallis test.prior to treatment. Such capability would be helpful in
clinical settings, allowing the selection of patients who
would only need a 24-week antiviral therapy regimen. This
would result in considerable cost savings and a reduction in
adverse effects.
According to American association for the study of liver
diseases (AASLD) guidelines,27 treatment should be dis-
continued for nonresponders who have limited chance of
SVR under PegIFN plus RBV treatment. For these types of
patients, treatment should be delayed until nonstructure
protein 3 and 4A (NS3/4A) protease inhibitors or polymerase
inhibitors are available.28,29 For better cost effectiveness
and patient welfare, it is important to predict those NR
patients prior to treatment. In the current study, we7805 69.26 24.56 0.0258
4151 21.7 85.87 0.0276
6669 181.23 81.36 0.0401
2524 7.57 61.13 0.0401
1627 32.48 14.38 0.0401
3241 209.58 96.69 0.0433
5337 222.15 99.87 0.044
3820 19.51 72.24 0.044
5943 76.47 35.3 0.0478
4732 13.84 28.09 0.0494
2783 11.9 16.67 0.0494
Virological responder Z HCV RNA undetectable at week 24
during treatment; non-responder Z HCV RNA detectable at
week 24 during treatment.
a Wilcoxon or Kruskal-Wallis test.
Figure 1 The number of peaks that changed in intensity
between the beginning (SO) and the end of treatment (SEOT) in
the sustained virological response (SVR) group and the non-SVR
group within the training group of patients.
Serum proteome predicts viral response in HCV-1 657predicted NR in 82% of patients prior to treatment by using
a cluster of 20 peptides.
Paradis et al23 were the first to conduct serum proteome
analysis to predict virological responses in patients with
chronic hepatitis C who were treated with PegIFN plus RBV.
They constructed an algorithm composed of two protein
peaks in the pretreatment serum, fibrosis stage, and ge-
notype that predicted response to treatment in 89% of all
patients. In the Paradis et al23 study, in addition to geno-
type 1 patients, they enrolled genotype 2 and 3 patients,
who are known to have high SVR rates (80e95%) to PegIFN
plus RBV treatment.4e6,10 It appears that we are not able to
obtain any additional advantages by using serum proteome
to predict treatment response in genotype 2 and 3 patients,
especially in Taiwan where SVR rates are around 84e95% in
genotype 2 patients.10 Genotype 3 is uncommon in Taiwan.9
By contrast, our study enrolled only genotype 1 patients.
We could predict SVR in 95% of validation group patients
using protein peaks alone.
Paradis et al23 identified a set of six peaks, the levels of
expression of which significantly differed between SVR and
non-SVR in pretreatment sera (p < 0.001). These peaks
were cM36764, cM36911, cM8905, cM32835, cM8776, andTable 7 Peptide peaks which were significantly different
between the serum protein profiles before treatment and at
the end of treatment in virological responders.
m/z mass, daltons Mean area
SO SEOT p valuea
4614 35.19 19.16 5.95  106
9288 1038.9 479.79 0.00016
8141 33.8 16.61 0.00205
9326 304.1 125.61 0.0025
7765 322.36 160.39 0.00715
7805 71.64 29.98 0.00911
4644 203.74 110.46 0.0205
Virological responder Z HCV RNA undetectable at week
24 during treatment; SO Z serum sample before starting
treatment; SEOT Z serum sample at the end of treatment.
a Wilcoxon or Kruskal-Wallis test.cM32500. However, there were three different peaks (m/z
6003, 4602, 10070) that were significantly different be-
tween the pretreatment serum protein profiles of SVR and
non-SVR patients in our study. There were discrepancies in
results between our study and Paradis et al.23 The possible
explanations are as follows. First, the races of the patient
population were different, which may lead to different
resultsdParadis et al23 enrolled patients from France, and
we enrolled patients from Taiwan. Second, the method to
analyze the proteome was different, which may also lead to
different resultsdParadis et al23 used surface-enhanced
LDIeTOF/MS, whereas we used MB-WCX for serum sample
processing and MALDIeTOF/MS for peptide profiling. Third,
Paradis et al23 enrolled patients with genotype 1 and non-
genotype 1; the duration of treatment in genotype 1 pa-
tients was 48 weeks and 24 weeks in genotype 2 or 3
patients. By contrast, we enrolled genotype 1 patients only
and the duration of treatment was 24 weeks.
Patel et al24 used LCeMS to analyze pretreatment sera.
They identified metaproteins that can predict SVR using an
area under the receiver operator characteristic curve
(AUROC) of 0.86e0.90, prior to commencing a PegIFN and
RBV combination therapy. These metaproteins included a
vitamin D binding protein, Alpha 2 HS glycoprotein, and
complement C5.24 In this research paper, the authors
claimed that these metaproteins may be more suitable for
clinical applications for the prediction of treatment
response rather than protein peaks identified in a previous
study23 because these protein “peaks” have not yet been
further characterized or validated.23 Using the meta-
proteins identified from the training group resulted in an
AUROC of 0.86 in the validation cohort and the researchers
correctly identified virological response in 71% of patients
without the favorable IL28B “responder” genotype.24 In the
current study, the protein peaks were not characterized
either; however, they nevertheless can serve in a potential
predictive role in HCV-1b patient treatment.
Our study showed significant differences in proteome
profiles throughout longitudinal serum samples in virolog-
ical responders, in patients with mild fibrosis, and in those
with mild necroinflammation, but there were no significant
differences in proteome profiles in those with severe
fibrosis or necroinflammation. The results might be
explained by a better response to antiviral therapy in mild
necroinflammation/fibrosis patients, which induced signif-
icant decreases in peaks during treatment. Similar findings
were noted in the Paradis et al study.23
In conclusion, longitudinal serumproteome differences
were noted in chronic HCV-1b patients with virological re-
sponders, mild fibrosis, and necroinflammation. Using pre-
treatment serum proteome profiling prior to treatment, we
were able to predict SVR and NR to PegIFN and ribavirin
therapy in chronic HCV-1b patients.Acknowledgments
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